In this issue:
Ibrutinib + bendamustine and rituximab in untreated MCL
Lisocabtagene maraleucel for R/R LBCL
A new dynamic prognostic index for DLBCL
Idasanutlin + cytarabine in R/R AML
MATRix for PCNSL: 7-year results of the IELSG32 trial
Real-world data for combined modality therapy for early Hodgkin lymphoma
Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma
Bortezomib in newly diagnosed T-cell ALL and lymphoma
Mortality among patients with low-grade follicular lymphoma
Please login below to download this issue (PDF)